JP7683882B2 - ストレスに対するセロトニン４受容体アゴニストの予防的有効性 - Google Patents

ストレスに対するセロトニン４受容体アゴニストの予防的有効性 Download PDF

Info

Publication number
JP7683882B2
JP7683882B2 JP2021560628A JP2021560628A JP7683882B2 JP 7683882 B2 JP7683882 B2 JP 7683882B2 JP 2021560628 A JP2021560628 A JP 2021560628A JP 2021560628 A JP2021560628 A JP 2021560628A JP 7683882 B2 JP7683882 B2 JP 7683882B2
Authority
JP
Japan
Prior art keywords
mice
epm
groups
administered
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021560628A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022527865A5 (enExample
JP2022527865A (ja
Inventor
デニー，クリスティン，エー．
ガーディアー，アラン，エム．
デイビッド，デニス，ジェイ．
メンデス－デイビッド，インディラ
フェイ，シャーリーン
チェン，ブリアナ，ケイ．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Columbia University
Original Assignee
Columbia University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Columbia University filed Critical Columbia University
Publication of JP2022527865A publication Critical patent/JP2022527865A/ja
Publication of JP2022527865A5 publication Critical patent/JP2022527865A5/ja
Application granted granted Critical
Publication of JP7683882B2 publication Critical patent/JP7683882B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021560628A 2019-04-09 2020-04-08 ストレスに対するセロトニン４受容体アゴニストの予防的有効性 Active JP7683882B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962831517P 2019-04-09 2019-04-09
US62/831,517 2019-04-09
US201962857075P 2019-06-04 2019-06-04
US62/857,075 2019-06-04
US201962910859P 2019-10-04 2019-10-04
US62/910,859 2019-10-04
PCT/US2020/027321 WO2020210393A1 (en) 2019-04-09 2020-04-08 Prophylactic efficacy of serotonin 4 receptor agonists against stress

Publications (3)

Publication Number Publication Date
JP2022527865A JP2022527865A (ja) 2022-06-06
JP2022527865A5 JP2022527865A5 (enExample) 2023-04-13
JP7683882B2 true JP7683882B2 (ja) 2025-05-27

Family

ID=72750568

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021560628A Active JP7683882B2 (ja) 2019-04-09 2020-04-08 ストレスに対するセロトニン４受容体アゴニストの予防的有効性

Country Status (8)

Country Link
US (1) US20220031684A1 (enExample)
EP (1) EP3952852B1 (enExample)
JP (1) JP7683882B2 (enExample)
CN (1) CN113924087A (enExample)
AU (1) AU2020271839B2 (enExample)
CA (1) CA3136328A1 (enExample)
MX (1) MX2021012394A (enExample)
WO (1) WO2020210393A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7821116B2 (ja) * 2020-04-07 2026-02-26 ザ トラスティーズ オブ コロンビア ユニバーシティー イン ザ シティー オブ ニューヨーク ストレス誘導性恐怖、うつ様行動および不安様行動の予防のための組成物および方法
EP4577305A4 (en) * 2022-08-25 2026-07-29 Univ Columbia COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND ANOTHER NEURODEGENERATIVE DISEASE
CN118105081B (zh) * 2024-03-04 2025-02-11 天津大学 一种情绪状态与神经电生理状态调节装置、验证系统及方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090170899A1 (en) 2004-09-14 2009-07-02 Guy Debonnel Stimulators of 5-HT4 receptors and uses thereof
US20180325844A1 (en) 2015-11-17 2018-11-15 The Trusttees of Columbia University in the City of New York Pharmacological prophylactics against stress-induced affective disorders and their associated symptoms

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2846559B1 (fr) * 2002-10-31 2007-06-15 Centre Nat Rech Scient Composition pharmaceutique pour la preparation d'un medicament destine a traiter et/ou a prevenir une pathologie liee a une conduite obsessionnelle
US9642862B2 (en) 2010-11-18 2017-05-09 White Mountain Pharma, Inc. Methods for treating chronic or unresolvable pain and/or increasing the pain threshold in a subject and pharmaceutical compositions for use therein

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090170899A1 (en) 2004-09-14 2009-07-02 Guy Debonnel Stimulators of 5-HT4 receptors and uses thereof
US20180325844A1 (en) 2015-11-17 2018-11-15 The Trusttees of Columbia University in the City of New York Pharmacological prophylactics against stress-induced affective disorders and their associated symptoms

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Guillaume Lucas et al.，Serotonin4 (5-HT4) Receptor Agonists Are Putative Antidepressants with a Rapid Onset of Action，Neuron，2007年，Vol.55, No.5，Pages 712-725
Jaclyn N. Highland et al.，Group II metabotropic glutamate receptor blockade promotes stress resilience in mice，Neuropsychopharmacology，2019年04月02日，Vol.44, No.10，Pages 1788-1796

Also Published As

Publication number Publication date
MX2021012394A (es) 2022-01-19
JP2022527865A (ja) 2022-06-06
EP3952852B1 (en) 2026-07-22
AU2020271839B2 (en) 2025-04-24
WO2020210393A1 (en) 2020-10-15
CA3136328A1 (en) 2020-10-15
EP3952852A4 (en) 2023-01-04
AU2020271839A1 (en) 2021-11-04
CN113924087A (zh) 2022-01-11
US20220031684A1 (en) 2022-02-03
EP3952852A1 (en) 2022-02-16

Similar Documents

Publication Publication Date Title
Petroianu et al. Neuropathic pain: Mechanisms and therapeutic strategies
Wolff et al. Ketamine: from medicine to misuse
US11110070B2 (en) Pharmacological prophylactics against stress-induced affective disorders and their associated symptoms
US12239614B2 (en) Pharmacological prophylactics against stress-induced affective disorders in females
JP2026021298A (ja) 全般性不安障害又は生命を脅かす疾患に関連しない他の不安のための心理療法を補助するためのリゼルギン酸ジエチルアミド（ｌｓｄ）及びｌｓｄ類似体の作用
JP7821116B2 (ja) ストレス誘導性恐怖、うつ様行動および不安様行動の予防のための組成物および方法
US20220031684A1 (en) Prophylactic efficacy of serotonin 4 receptor agonists against stress
KR20100059830A (ko) 도파민 수용체 리간드를 함유하는 약학적 조성물 및 도파민 수용체 리간드를 사용한 치료 방법
CA2708323C (en) 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide for the treatment of post-traumatic stress disorder
US20220071932A1 (en) Compositions and Methods Against Stress-Induced Affective Disorders and Their Associated Symptoms
Beretta et al. Rescuing epileptic and behavioral alterations in a Dravet syndrome mouse model by inhibiting eukaryotic elongation factor 2 kinase (eEF2K)
Pakri Mohamed et al. Novel pharmacotherapeutic approaches in treatment of alcohol addiction
US9517265B2 (en) Methods for the prevention and/or treatment of memory impairment
US20200316087A1 (en) Novel combination therapy for anxiety disorders, epilepsy, and pain
Amaev The Effects of Psychedelic-Assisted Therapy on Illness and Death Anxiety
Cameron Psychedelics and novel non-hallucinogenic analogs for treating neuropsychiatric disorders
Cruz Impact of Psychoactive Drugs on Mental Health
Nackenoff Determining the role of serotonin in antidepressant action, as revealed utilizing the SERT Met172 mouse model
Linge Méndez et al. Cannabidiol induces rapid-acting antidepressant-like effects and enhances cortical 5-HT/glutamate neurotransmission: role of 5-HT1A receptors
Morrison downloaded from the King’s Research Portal at https://kclpure. kcl. ac. uk/portal

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230405

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230405

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240305

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240605

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240801

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250221

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250408

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250507

R150 Certificate of patent or registration of utility model

Ref document number: 7683882

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150